America's clampdown on tax inversions

The US government has issued new rules making it harder for American companies to cut their tax bill by relocating their headquarters.

President Barack Obama's administration has issued new rules to tackle the tax inversion loophole'. This is the practice whereby US firms merge with foreign peers and move their headquarters overseas to lower their domestic tax bill and put foreign earnings beyond the reach of the US taxman.

The tweaks make it harder for a deal to qualify as an inversion, and for firms to access their foreign cash without it being taxed. The government has acted unilaterally, as Congress is split on tax reform.

What the commentators said

The US government "has rained on the parade of UK companies that have attracted transatlantic interest based on the portability of earnings and cash as well as strategic rationale", said Alison Smith in the FT.

So shares in drug giants Shire and AstraZeneca "shivered" this week, on fears that their respective US suitors AbbVie and Pfizer might walk away from bids.

The Shire deal "looks the safer bet" given AbbVie's emphasis on the strategic fit. Pfizer, by contrast, is unlikely to be able to afford its quarry now that costs are set to rise.

But how effective is this clampdown really? Lawyers at Wickersham & Taft LLP, cited by The Wall Street Journal, reckon "most companies should be able to navigate the [changes] and complete a successful inversion with proper planning".

A key stumbling block is that, with Congress at loggerheads on the issue, it is impossible for the Treasury to stop such deals happening altogether. Don't expect that to change, said James Moore in The Independent. "Congress finds difficulty in agreeing on anything more substantial than a lunch menu let alone complex rules on corporation tax."

Recommended

AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
Biotech stocks

AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion

AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge r…
17 Dec 2020
Beware: inflation is starting to stir in the US
Inflation

Beware: inflation is starting to stir in the US

With US consumer prices up by 1.4% in the last year, concern about inflation is now everywhere.
22 Jan 2021
Inflation looks likely to take off this year – but there’s one key risk
Inflation

Inflation looks likely to take off this year – but there’s one key risk

With the world’s governments spending money hand over fist, inflation looks certain to take off at some point. But China could change all that. John S…
19 Jan 2021
Forget austerity – governments and central banks have no intention of cutting back
Global Economy

Forget austerity – governments and central banks have no intention of cutting back

Once the pandemic is over will we return to an era of austerity to pay for all the stimulus? Not likely, says John Stepek. The money will continue to …
15 Jan 2021

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
The world’s fund managers are getting very bullish – be careful out there
Stockmarkets

The world’s fund managers are getting very bullish – be careful out there

The latest survey of fund managers shows them to be extremely bullish on all the same things. And that, says John Stepek, means the market is in dange…
21 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021